MATINAS BIOPHARMA HOLDINGS, INC. Contingent Consideration Classified as Equity, Fair Value Disclosure
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $753.35 thousand as of 2015-12-31, per its 10-K filed 2018-03-16.
Discontinued › Notes › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2018-03-16
- 2015-12-31: Contingent Consideration Classified as Equity, Fair Value Disclosure $753.35K.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2015-12-31 | $753.35K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |